🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. OPDIVO 10 mg/mL concentrate for solution for infusion., BDC-1001, OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bolt Biotherapeutics

    Advanced HER2-Expressing Solid Tumors.

    phase 2 small molecule active

    1 trial

  2. OPDIVO 10 mg/mL concentrate for solution for infusion., JNJ-63723283, Zr89

    Disc Medicine

    Patients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy.

    phase 2 small molecule active

    1 trial

  3. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  4. OPRX-106

    Protalix BioTherapeutics

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  5. ORKA-001

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    2 trials

  6. ORKA-001 Induction Dose

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  7. ORKA-001, Placebo for ORKA-001

    Oruka Therapeutics

    Moderate-to-Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  8. ORKA-002

    Oruka Therapeutics

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  9. ORSERDU 86 mg film-coated tablets, ABEMACICLIB, ABEMACICLIB, ORSERDU 345 mg film-coated tablets, ABEMACICLIB

    Stemline Therapeutics B.V.

    Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  10. ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Stemline Therapeutics B.V.

    metastatic breast cancer

    phase 2 small molecule active

    1 trial

  11. ORY-2001 Low dose

    BRIGHT MINDS BIOSCIENCES INC.

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  12. OT-101

    Oncotelic Therapeutics

    COVID-19

    phase 2 small molecule active

    1 trial

  13. OT-101

    Oncotelic Therapeutics

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  14. OXALIPLATIN, AFLIBERCEPT, PANITUMUMAB, BEVACIZUMAB, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, IRINOTECAN, FLUOROURACIL, CETUXIMAB, AVELUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  15. Octreotide Acetate

    United Therapeutics Europe Ltd

    Liver Transplantation

    phase 2 small molecule active

    1 trial

  16. Olaparib

    United Therapeutics Europe Ltd

    Bile Duct Adenocarcinoma

    phase 2 small molecule active

    1 trial

  17. Olinciguat

    Cyclerion Therapeutics

    Achalasia

    phase 2 small molecule terminated

    1 trial

  18. Olutasidenib

    Atrium Therapeutics

    IDH1 Mutation

    phase 2 small molecule active

    1 trial

  19. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Targeted Therapy

    phase 2 small molecule active

    1 trial

  20. Olverembatinib

    The First People's Hospital of Lianyungang

    Myeloproliferative Neoplasm

    phase 2 small molecule active

    1 trial

  21. Onapristone

    Context Therapeutics

    ER-positive Breast Cancer

    phase 2 small molecule terminated

    1 trial

  22. Onapristone ER

    Context Therapeutics

    Granulosa Cell Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  23. Ondansetron (ODFS)

    Aquestive Therapeutics

    Nausea and Vomiting, Postoperative

    phase 2 small molecule completed

    1 trial

  24. Ondansetron Aurobindo 8 mg Filmtabletten, Dexamethasone 4 mg tablets, ZYPREXA 2.5 mg coated tablets, SELINEXOR, Bortezomib Accord 3.5 mg powder for solution for injection

    Karyopharm Therapeutics Inc

    Penta-refractory multiple myeloma and triple-class refractory multiple myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources